Urinary excretion of N-acetyl-beta-D-glucosaminidase and alpha1-microglobulin in children with proliferative blood diseases.
The purpose of the study was to estimate the urinary excretion of NAG and alpha-1M among children who suffer from proliferative blood diseases. The group of the examined children included those who went through a viral hepatitis (VH) and who are or were treated by means of cytostatic drugs. The study comprised 73 children aged from 4 to 18 (average 11.7+/-3.5. There were 70 children with the diagnosis of leukemia and 3 with the diagnosis of non-Hodgkin lymphoma. The examined group was divided according to the stage of treatment of a basic disease. Group I--22 children who are treated currently or whose treatment has been completed recently. Group II--51 children whose treatment was completed over two years ago. In group II there were 4 subgroups distinguished depending on positive antigenemia HBs and the presence of HCV antibodies. There were no clinical or biochemical features of damage of renal function observed among any of the children. The testing group consisted of 70 healthy children who were selected regarding age and sex. The urinary excretion of NAG and alpha-1M was estimated in the second morning portion of urine and it was presented as NAG/creatinine and alpha-1M/creatinine ratio. The results of the research underwent the statistical analysis by means of a t-Student test. It was stated that the urinary excretion of NAG and alpha-1M was higher among children who currently are or were treated by means of cytostatics drugs. It was also stated that the urinary excretion of NAG was higher among the children who went through viral hepatitis C in comparison with HBs antigen carriers. Similarly, the urinary excretion of alpha-1M was higher among children with positive markers of viral hepatitis B and C markers in comparison with a group of HBs antigen carriers.
Zajaczkowska
Małgorzata
M
Department of Pediatric Nephrology, Medical University of Lublin.
Stefaniak
Jolanta
J
Sikora
Przemysław
P
Choma-Smaga
Marta
M
Filiks-Litwin
Barbara
B
Szajner-Milart
Irena
I
Borzecka
Halina
H
D000118:Acetylglucosaminidase / Q000652:urine*; D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000652:urine* / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000652:urine* / Q000821:virology; D008297:Male; D008562:Membrane Glycoproteins / Q000652:urine*; D014360:Trypsin Inhibitor, Kunitz Soybean / Q000652:urine*
D000970:Antineoplastic Agents; D006510:Hepatitis B Antibodies; D018937:Hepatitis C Antibodies; D008562:Membrane Glycoproteins; C109148:SPINT2 protein, human; D014360:Trypsin Inhibitor, Kunitz Soybean; D000118:Acetylglucosaminidase